Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 12060432 Combination therapies with anti-CD38 antibodies

Patent 12060432 was granted and assigned to Janssen Biotech on August, 2024 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

0

Patent attributes

Patent Applicant

Janssen Biotech

0

Current Assignee

Janssen Biotech

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

Parul Doshi0

Date of Patent

August 13, 2024

0

Patent Application Number

170150170

Date Filed

September 8, 2020

0

Patent Citations

US Patent 7829693 Compositions and methods for inhibiting expression of a target gene

0

US Patent 7183387 Polypeptide variants with altered effector function

0

US Patent 7223397 Potentiation of anti-CD38-Immunotoxin cytotoxicity

0

US Patent 7829673 Antibodies against CD38 for treatment of multiple myeloma

0

US Patent 10781261 Subcutaneous formulations of anti-CD38 antibodies and their uses

0

US Patent 10793630 Anti-CD38 antibodies for treatment of acute myeloid leukemia

0

US Patent 10800851 Combination therapies with anti-CD38 antibodies

0

US Patent 11021543 Immune modulation and treatment of solid tumors with antibodies that specifically bind CD38

0

...

Patent Primary Examiner

0

CPC Code

0

0

0

0

0

0

Patent abstract

The present invention relates to combination therapies with anti-CD38 antibodies.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 12060432 Combination therapies with anti-CD38 antibodies

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool

By using this site, you agree to our Terms of Service.